On 1 January approximately 30 pharmaceutical companies raised the prices of hundreds of drugs in the US by an average of 6.3%, following a year of price freezes.

In July, Pfizer reversed its planned price hikes in July following pressure from President Donald Trump and many other large drug makers copied.

The percentage increase is higher than the country’s inflation rate. The Wall Street Journal has revealed that Allergan was the first to act.

Rx Savings Solution CEO Michael Rea told Reuters: “Requests and public shaming haven’t worked [to lower drug prices]. We expect the number of 2019 increases to be even greater than in past years.”

According to Reuters, in November last year, 28 drug makers submitted plans to California authorities to raise drug prices in a minimum of 60 days; a law was passed in 2018 requiring companies to notify payers of significant increases to the list prices of drugs. The 28 companies include large names such as Novartis, Bayer, GlaxoSmithKline and AstraZeneca.

In addition, Pfizer announced in mid-December its plan to increase the price of 41 of its medicines by 5% on 15 January.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company’s chairman and CEO Ian Read said in the statement: “We believe the best means to address affordability of medicines is to reduce the growing out-of-pocket costs that consumers are facing due to high deductibles and co-insurance, and ensure that patients receive the benefit of rebates at the pharmacy counter.”

It is expected the government and legislature in the US will react strongly against these moves. Lowering drug prices was both a priority in President Trump’s presidential campaign, and something he has continued to push for since, and for the Democrats who recently gained control of the House of Representatives.